ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

14 links0 made here, not in the record26 judgments2 judges (the rules as one: Rule based)4 record changes seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 5Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT07793942A Clinical Trial of MK-2010Alone and With OtherTreatments in ParticipantsWith Advanced Solid Tumors(MK-2010-002)Merck Sharp & Dohme LLCPhase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 5 · ClinicalTrials.gov record · Version of 2026-10-05Oct 8 · ClinicalTrials.gov record · Version of 2026-10-08Nov 5 · ClinicalTrials.gov record · Version of 2026-11-05Nov 16 · ClinicalTrials.gov record · Version of 2026-11-16Version of 2026-11-16CONDITIONSMalignant NeoplamNo longer in the registry's filing›Nov 14 · Rule based · Not readNot readAdvanced Solid TumorsNo longer in the registry's filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseDRUGSAnti-PD-1/Anti-VEGF Bispeci…Entry “MK-2010”, read by our name rule›Nov 10 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPembrolizumabIntervention entry›Nov 10 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorFluorouracilEntry “5-Fluorouracil”, read by our n…›Nov 10 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundOxaliplatinIntervention entry›Nov 10 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundBelzutifanIntervention entry›Nov 10 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerGemcitabineIntervention entry›Nov 10 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCisplatinIntervention entry›Nov 10 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCarboplatinIntervention entry›Nov 10 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundPaclitaxelIntervention entry›Nov 10 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundAlbumin-Bound PaclitaxelEntry “Nab-paclitaxel”, read by our n…›Nov 10 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundPemetrexedIntervention entry›Nov 10 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundEpinephrineIntervention entry›Nov 10 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “MK-2010”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Oct 5The record itselfClinicalTrials.gov recordVersion of 2026-10-05Record change
Oct 8The record itselfClinicalTrials.gov recordVersion of 2026-10-08Record change
Nov 5The record itselfClinicalTrials.gov recordVersion of 2026-11-05Record change
Nov 10Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010Claude Opus 5.5TestedCurrent
Nov 10PembrolizumabClaude Opus 5.5ComparatorCurrent
Nov 10FluorouracilClaude Opus 5.5BackgroundCurrent
Nov 10OxaliplatinClaude Opus 5.5BackgroundCurrent
Nov 10BelzutifanClaude Opus 5.5Background · partnerCurrent
Nov 10GemcitabineClaude Opus 5.5BackgroundCurrent
Nov 10CisplatinClaude Opus 5.5BackgroundCurrent
Nov 10CarboplatinClaude Opus 5.5BackgroundCurrent
Nov 10PaclitaxelClaude Opus 5.5BackgroundCurrent
Nov 10Albumin-Bound PaclitaxelClaude Opus 5.5BackgroundCurrent
Nov 10PemetrexedClaude Opus 5.5BackgroundCurrent
Nov 10EpinephrineClaude Opus 5.5BackgroundCurrent
Nov 14Malignant NeoplamRule based · condition-kind ruleNot readCurrent
Nov 14Advanced Solid TumorsRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 16The record itselfClinicalTrials.gov recordVersion of 2026-11-16Record change
Nov 18Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010Rule based · role ruleTestedAgrees
Nov 18PembrolizumabRule based · role ruleComparatorAgrees
Nov 18FluorouracilRule based · role ruleTestedOverridden
Nov 18OxaliplatinRule based · role ruleTestedOverridden
Nov 18BelzutifanRule based · role ruleBackgroundAgrees
Nov 18GemcitabineRule based · role ruleBackgroundAgrees
Nov 18CisplatinRule based · role ruleBackgroundAgrees
Nov 18CarboplatinRule based · role ruleBackgroundAgrees
Nov 18PaclitaxelRule based · role ruleBackgroundAgrees
Nov 18Albumin-Bound PaclitaxelRule based · role ruleBackgroundAgrees
Nov 18PemetrexedRule based · role ruleBackgroundAgrees
Nov 18EpinephrineRule based · role ruleBackgroundAgrees

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.